Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative envafolimab plus SOX for locally advanced gastric or gastroesophageal junction adenocarcinoma
ISRCTN14298588Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab, oxaliplatin and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathologic complete response rate. Started Feb 2024; status: completed.
02
Drugs
envafolimaboxaliplatintegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ISRCTN14298588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14298588.